A recent study showed that the inhibitory effect of carvacrol on the cell cycle is associated with the downregulation of cyclinD1 and CDK4 and the upregulation of suppressor protein p21 in androgen-independent PC-3 human prostate cancer. Here, CDK4 is linked to prostate carcinoma.